

## AMENDMENTS

### In the Specification:

Please replace paragraph [0011] with the following amended paragraph:

[0011] The present invention is based, in part, on the recognition that integrin  $\alpha_v\beta_3$  antagonists potentiate and synergize with certain anti-inflammatory treatments including, in particular, anti-TNF- $\alpha$  agents and methotrexate. Thus, the invention encompasses treatment protocols that provide better prophylactic and therapeutic profiles than current single agent therapies for autoimmune and/or inflammatory disorders. The invention provides combination therapies for prevention, treatment or amelioration of one or more symptoms associated with an autoimmune or inflammatory disorder in a subject, said combination therapies comprising administering to said subject one or more integrin  $\alpha_v\beta_3$  antagonists and one or more prophylactic or therapeutic agents other than integrin  $\alpha_v\beta_3$  antagonists. In particular, the invention provides combination therapies for prevention, treatment or amelioration of one or more symptoms associated with an autoimmune or inflammatory disorder in a subject, said combination therapies comprising administering to said subject an integrin  $\alpha_v\beta_3$  antagonist, preferably VITAXIN™ (~~etaraeizumab~~), and at least one other prophylactic or therapeutic agent which has a different mechanism of action than the integrin  $\alpha_v\beta_3$  antagonist.